These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 18432640)

  • 1. Commonly used detergents.
    Coligan JE
    Curr Protoc Immunol; 2001 May; Appendix 1():Appendix 1D. PubMed ID: 18432640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA type of EBV-transformed human B cell lines.
    Hurley CK; Johnson AH
    Curr Protoc Immunol; 2001 May; Appendix 1():Appendix 1G. PubMed ID: 18432643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Commonly used detergents.
    Coligan JE
    Curr Protoc Protein Sci; 2001 May; Appendix 1():Appendix 1B. PubMed ID: 18429062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human T cell receptor-gamma delta-expressing T-cell lines recognize MHC-controlled elements on autologous EBV-LCL that are not HLA-A, -B, -C, -DR, -DQ, or -DP.
    Lam V; DeMars R; Chen BP; Hank JA; Kovats S; Fisch P; Sondel PM
    J Immunol; 1990 Jul; 145(1):36-45. PubMed ID: 1694208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epstein-Barr virus-induced lymphoblastoid cell lines from seropositive adult donors and their HLA-antigens.
    Akiyama N; Ohsawa N; Kusaba R; Inou T; Takada M
    Jpn J Exp Med; 1981 Feb; 51(1):1-7. PubMed ID: 6273617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-D typing using Epstein-Barr virus-induced lymphoblastoid cell lines.
    Akiyama N; Ohsawa N; Samaru Y; Kusaba R
    Jpn J Exp Med; 1982 Apr; 52(2):67-73. PubMed ID: 6288983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr-virus-transformed lymphoblastoid cell lines derived from patients with X-linked agammaglobulinaemia and Wiskott-Aldrich syndrome: responses to B cell growth and differentiation factors.
    Lau YL; Shields JG; Levinsky RJ; Callard RE
    Clin Exp Immunol; 1989 Feb; 75(2):190-5. PubMed ID: 2539277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional and molecular characterization of B cell-responsive V delta 1+ gamma delta T cells.
    Orsini DL; van Gils M; Kooy YM; Struyk L; Klein G; van den Elsen P; Koning F
    Eur J Immunol; 1994 Dec; 24(12):3199-204. PubMed ID: 7528674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common and idiosyncratic patterns of cytokine gene expression by Epstein-Barr virus transformed human B cell lines.
    Rochford R; Cannon MJ; Sabbe RE; Adusumilli K; Picchio G; Glynn JM; Noonan DJ; Mosier DE; Hobbs MV
    Viral Immunol; 1997; 10(4):183-95. PubMed ID: 9473149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphipathic agents for membrane protein study.
    Sadaf A; Cho KH; Byrne B; Chae PS
    Methods Enzymol; 2015; 557():57-94. PubMed ID: 25950960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) as stimulating cells in mixed lymphocyte culture (MLC).
    Wasik M; Matej H; Duś D; Myc A
    Arch Immunol Ther Exp (Warsz); 1983; 31(6):879-85. PubMed ID: 6331341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of allogeneic restriction of human cytotoxic T cell clones specific for Epstein Barr virus.
    Tanaka Y; Sugamura K; Hinuma Y
    J Immunol; 1982 Mar; 128(3):1241-5. PubMed ID: 6173428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
    Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electron paramagnetic resonance study of the surface hydration of Triton X-100 micelles in water with added monovalent alkali salts.
    Jose BJ; Bales BL; Peric M
    J Phys Chem B; 2009 Oct; 113(40):13257-62. PubMed ID: 19791821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immortalized Epstein-Barr virus-positive B-cell lines obtained by prolonged culture of peripheral blood mononuclear cells from human immunodeficiency virus type 1-positive patients.
    Ruibal-Ares B; Belmonte L; Baré P; Scolnik M; Palacios MF; Bayo-Hanza C; Galmarini CM; Mendez G; de Bracco MM
    J Hum Virol; 2001; 4(4):200-13. PubMed ID: 11694848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies.
    Odum N; Ledbetter JA; Martin P; Geraghty D; Tsu T; Hansen JA; Gladstone P
    Eur J Immunol; 1991 Sep; 21(9):2121-31. PubMed ID: 1889460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary CD4+ T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells.
    MacArthur GJ; Wilson AD; Birchall MA; Morgan AJ
    J Virol; 2007 May; 81(9):4766-75. PubMed ID: 17314172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accessory function of human leukemic cell lines: properties of B and B-K562 hybrid cell lines.
    Wakasugi H; Dokhelar MC; Garson D; Harel-Bellan A; Fradelizi D; Tursz T
    Eur J Immunol; 1985 Mar; 15(3):256-61. PubMed ID: 3872216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro induction of HLA-restricted cytotoxic T lymphocytes against autologous Epstein-Barr Virus transformed B lymphoblastoid cell line.
    Fukukawa T; Hirano T; Sakaguchi N; Teranishi T; Tsuyuguchi I; Nagao N; Naito N; Yoshimura K; Okubo Y; Tohda H; Oikawa A
    J Immunol; 1981 May; 126(5):1697-701. PubMed ID: 6163815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus (EBV) and human hematopoietic cell lines: a review.
    Tatsumi E
    Hum Cell; 1992 Mar; 5(1):79-86. PubMed ID: 1329932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.